Novavax reported $331.94M in Loan Capital for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Loan Capital Change
Adma Biologics ADMA:US $ 93.88M 0.46M
Agenus AGEN:US $ 18.95M 0.03M
Astrazeneca AZN:US 24.6B 6.73B
AstraZeneca AZN:LN 24601M 6727M
Biocryst Pharmaceuticals BCRX:US $ 263.66M 9.32M
BioSpecifics Technologies BSTC:US 0 0
Dynavax Technologies DVAX:US $ 219.96M 40.07M
Genocea Biosciences GNCA:US $ 6.49M 1.16M
GlaxoSmithKline GSK:LN 20442M 2605M
Kindred Biosciences KIN:US $ 15.35M 1.58M
Mannkind MNKD:US $ 280.26M 45.66M
Minerva Neurosciences NERV:US $ 0M 0M
Moderna Inc MRNA:US $ 328M 190M
Novartis NVS:US $ 26491M 908M
Novavax NVAX:US $ 331.94M 7.15M
Pain Therapeutics PTIE:US $ 0M 0M
Peregrine Pharmaceuticals PPHM:US $ 138.81M 41.86M
Sarepta Therapeutics SRPT:US $ 1092.98M 1.88M